The Claim
In healthy women aged 50–85, intermittent administration of 10 mg weekly compounded rapamycin over 48 weeks is associated with a probable reduction in self-reported pain, with a mean improvement of 8.07 points (95% CI: 3.04–13.10) on the SF-36 pain scale, suggesting a potential benefit for age-related pain management.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a low weekly dose of a drug called rapamycin for a year might help reduce pain in healthy women over 50, based on how they reported feeling.
See the scientific wording
Intermittent 10 mg weekly compounded rapamycin for 48 weeks probably reduces self-reported pain in healthy women aged 50–85, with a mean improvement of 8.07 points (95% CI: 3.04–13.10) on the SF-36 pain scale, suggesting a potential role in age-related pain management.
What the research says
1 studyStudy: Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
The study gave 10 mg of rapamycin weekly for 48 weeks to healthy women and found less self-reported pain, which supports the idea that this treatment helps with age-related pain.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.